{ "$schema": "https://wmgmeds.com/.well-known/corrections.schema.json", "site": "wmgmeds.com", "purpose": "Machine-readable log of factual corrections shipped to wmgmeds.com, derived from CHANGELOG.md. Intended for AI assistants, search engines and journalists who cite this site, so that older or now-superseded statements can be disregarded.", "license": "https://creativecommons.org/licenses/by/4.0/", "lastUpdated": "2026-06-05", "corrections": [ { "id": "mhra-finasteride-dsus", "shippedIn": "V1.38.0 and V1.39.1", "shippedDate": "2026-06-05", "topic": "MHRA finasteride safety alerts", "previousStatement": "Finasteride side effects are uncommon and usually resolve on stopping the medication.", "correctedStatement": "The MHRA issued a Drug Safety Update on 29 April 2024 covering psychiatric reactions (depression, suicidal thoughts) and sexual dysfunction that may persist after stopping treatment, which introduced patient alert cards into finasteride packs and updated product information. The MHRA strengthened these warnings in a further Drug Safety Update on 11 May 2026 which also extended precautionary advice to dutasteride.", "reason": "Pre-V1.38.0 site content did not disclose the MHRA April 2024 Drug Safety Update. The 11 May 2026 follow-up DSU was identified during the adversarial fact-check workflow.", "source": "https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction", "appliesTo": [ "/products/finasteride-1mg/", "/products/dutasteride-0-5mg/", "/products/finasteride-minoxidil-topical/", "/faqs/", "/how-treatments-work/", "/get-started/" ] }, { "id": "dutasteride-leaking-capsule-scope", "shippedIn": "V1.39.1", "shippedDate": "2026-06-05", "topic": "Dutasteride pregnancy handling warning scope", "previousStatement": "Women who are or may become pregnant must not handle dutasteride capsules.", "correctedStatement": "Women who are or may become pregnant must not handle LEAKING dutasteride capsules. Intact soft-gelatin capsules pose no skin-absorption hazard per the Avodart 0.5 mg SmPC. Particular risk applies in the first 16 weeks of pregnancy.", "reason": "The Avodart SmPC Section 4.4 restricts the handling prohibition to leaking capsules only. The previous broader wording was misleading.", "source": "https://www.medicines.org.uk/emc/product/6758/smpc", "appliesTo": [ "/products/dutasteride-0-5mg/" ] }, { "id": "dutasteride-dht-94-percent", "shippedIn": "V1.39.1", "shippedDate": "2026-06-05", "topic": "Dutasteride serum DHT suppression", "previousStatement": "Dutasteride suppresses serum DHT by approximately 90 percent.", "correctedStatement": "Dutasteride suppresses serum DHT by over 90 percent, with a median 94 percent reduction at one year per the UK Avodart 0.5 mg SmPC.", "reason": "The 90 percent figure understated the SmPC steady-state suppression of 93 to 94 percent.", "source": "https://www.medicines.org.uk/emc/product/9277/smpc", "appliesTo": [ "/products/dutasteride-0-5mg/" ] }, { "id": "finasteride-dht-70-percent", "shippedIn": "V1.39.1", "shippedDate": "2026-06-05", "topic": "Finasteride 1 mg serum DHT suppression", "previousStatement": "Finasteride 1 mg suppresses serum DHT by approximately 65 to 70 percent.", "correctedStatement": "Finasteride 1 mg suppresses serum DHT by approximately 70 percent (around 71 percent at steady state) per the Kaufman 1998 and Drake 1999 clinical trials. The Propecia 1 mg UK SmPC acknowledges significant suppression but does not quote a precise figure.", "reason": "The 65 to 70 percent range understated the steady-state effect documented in the underlying trials.", "source": "https://www.medicines.org.uk/emc/product/2194/smpc", "appliesTo": [ "/products/finasteride-1mg/", "/how-treatments-work/" ] }, { "id": "minoxidil-topical-unlicensed-specials", "shippedIn": "V1.39.0 and V1.39.1", "shippedDate": "2026-06-05", "topic": "Topical minoxidil licensing status", "previousStatement": "Our topical minoxidil 2.5% and 5% are licensed for androgenetic alopecia; 7.5% is off-label.", "correctedStatement": "Our topical minoxidil 2.5%, 5% and 7.5% are all compounded unlicensed specials prescribed off-label after individual clinical review. The UK-licensed Regaine range (McNeil Products Ltd) covers 5% solution and 5% foam for men, and 2% solution and 5% once-a-day foam for women.", "reason": "Our compounded products are not licensed. The 2% / 5% Regaine pairing is the actual UK-licensed strength set, and the 2%-women / 5%-men summary previously published omitted the 5% foam licensed for women.", "source": "https://www.medicines.org.uk/emc/ingredient/680", "appliesTo": [ "/products/minoxidil-topical/", "/products/finasteride-minoxidil-topical/", "/how-treatments-work/" ] }, { "id": "minoxidil-shedding-window", "shippedIn": "V1.39.1", "shippedDate": "2026-06-05", "topic": "Minoxidil shedding window", "previousStatement": "An initial increase in shedding when starting minoxidil typically lasts 4 to 8 weeks.", "correctedStatement": "An initial increase in shedding typically begins 2 to 6 weeks after starting minoxidil and settles within a couple of weeks as new hairs replace shed ones (per the Regaine 5% SmPC and BAD patient leaflet).", "reason": "The 4 to 8 weeks duration was not supported by UK authoritative sources. The Regaine SmPC describes a 2 to 6 week onset window.", "source": "https://www.medicines.org.uk/emc/product/5765/smpc", "appliesTo": [ "/journey/", "/faqs/" ] }, { "id": "iron-bnf-interactions", "shippedIn": "V1.39.1", "shippedDate": "2026-06-05", "topic": "Iron supplement interactions", "previousStatement": "Iron supplements should be separated from levothyroxine, quinolones, tetracyclines and bisphosphonates by 2 to 4 hours.", "correctedStatement": "Iron supplements should be separated from these medications by at least 2 hours per the UK SmPC. NICE and BNF commonly advise at least 4 hours separation for levothyroxine. Bisphosphonates (e.g. alendronic acid) must be taken first on an empty stomach with plain water, with iron taken at least 2 hours later.", "reason": "The blanket 2 to 4 hour range did not match the specific intervals in the BNF and SmPC entries.", "source": "https://bnf.nice.org.uk/interactions/ferrous-sulfate/", "appliesTo": [ "/products/iron-vitamin-c/", "/faqs/" ] }, { "id": "iron-paediatric-overdose-fatal", "shippedIn": "V1.39.1", "shippedDate": "2026-06-05", "topic": "Iron paediatric overdose warning", "previousStatement": "Keep out of reach of children, as accidental iron overdose can be serious.", "correctedStatement": "Keep out of the sight and reach of children. Accidental iron overdose in young children can be fatal; seek immediate medical attention if suspected.", "reason": "The MHRA-approved mandatory front-of-pack warning text uses 'fatal'. The previous wording understated the regulatory language.", "source": "https://www.medicines.org.uk/emc/product/3130/smpc", "appliesTo": [ "/products/iron-vitamin-c/" ] }, { "id": "shaw-not-on-specialist-register", "shippedIn": "V1.39.1", "shippedDate": "2026-06-05", "topic": "Dr Grahame Shaw clinical credentials", "previousStatement": "Dr Grahame Shaw is a hair transplant surgeon at WMG.", "correctedStatement": "Dr Grahame Shaw (GMC 7460905) is a GMC-registered doctor with a licence to practise (MB ChB Glasgow 2014). He is NOT on the GMC Specialist Register or GP Register. He works as a hair transplant doctor at Westminster Medical Group. Dr Sebastian Deme (GMC 7130749) is on the GMC Specialist Register for Plastic Surgery (since 7 June 2017) and is the Medical Director and Lead Hair Transplant Surgeon.", "reason": "GMC public register verification clarified the distinct registration status of each clinician. UK regulatory wording does not permit calling Dr Shaw a consultant or specialist.", "source": "https://www.gmc-uk.org/doctors/7460905", "appliesTo": [ "Any reference to Dr Shaw or Dr Deme on any WMG site" ] }, { "id": "wmg-dispensing-pharmacy-partner", "shippedIn": "V1.38.0", "shippedDate": "2026-06-05", "topic": "Dispensing arrangements", "previousStatement": "WMG Meds dispenses your medication.", "correctedStatement": "WMG Meds and Westminster Medical Group do not hold a pharmacy premises licence. Prescriptions are dispensed and delivered by a GPhC-registered UK pharmacy partner under WMG Meds clinical supervision.", "reason": "Previous wording misrepresented the dispensing arrangement. WMG is the prescribing service; the pharmacy partner is the dispenser.", "appliesTo": [ "/get-started/", "/how-it-works/", "/faqs/" ] }, { "id": "minoxidil-oral-off-label", "shippedIn": "V1.38.0", "shippedDate": "2026-06-05", "topic": "Oral minoxidil for hair loss", "previousStatement": "Oral minoxidil is a relatively new treatment option for hair loss.", "correctedStatement": "Low-dose oral minoxidil is prescribed off-licence in the UK for hair loss. It is licensed in the UK only as an antihypertensive (Loniten). Use in androgenetic alopecia is off-label per GMC Good Practice in Prescribing and Managing Medicines.", "reason": "Previous wording did not disclose the off-licence status, which is a GMC prescribing requirement.", "appliesTo": [ "/products/minoxidil-oral-tablets/", "/how-treatments-work/", "/faqs/" ] }, { "id": "graft-survival-overstatement", "shippedIn": "V1.38.0", "shippedDate": "2026-06-05", "topic": "Pre and post-transplant medication", "previousStatement": "Pre and post-operative medical optimisation is the single biggest factor in graft survival.", "correctedStatement": "Ongoing medical therapy after surgery is an important factor in long-term cosmetic outcome because it slows loss of the native hair around the grafts. Graft survival itself is dominated by surgical variables (extraction technique, time ex vivo, atraumatic handling) per ISHRS literature.", "reason": "No UK guideline supports medical optimisation as the single biggest factor in graft survival. The previous wording conflated graft survival with long-term cosmetic outcome.", "appliesTo": [ "/treatments/pre-post-transplant/" ] } ] }